title: [Expression of the human dystrophin gene in mdx mouse muscle fibers after transfection using liposomes and synthetic oligopeptides].
abstract: The number of dysrophin-positive fibers appearing in the femoral quadriceps muscle of mdx mice after injection of the full-length human dystrophin cDNA within the pHSADy plasmid was examined by means of immunohystochemical techniques. Transfection was carried out using lipofectamine (LFA), or synthetic oligopeptide complexes that provided the condensation of plasmid DNA (K8) and its release from endosomes gopeptide complexes that provided the condensation of plasmid DNA (K8) and its release from endosomes (JTS1). The LFA + pHSADy at a dose of 10 micrograms DNA did not affect the number of dystrophin-positive fibers at the site of injection (0.6-0.8%), whereas it caused a statistically significant increase in the number of these fibers in the same muscle of the contralateral leg (up to 2.3%). Injection of the SO + pHSADy complex resulted in the occurrence of dystrophin-positive muscle fibers characterized by a heterogeneous content and the distribution of dystrophin. The greatest number of dystrophin-positive fibers (about 16%) was observed under a ratio of pHSADy to K8 of 1:3 or 1:4. The observed maximal number of dystrophin-positive fibers after a single injection of SO + pHSADy was 3.8%, and it was 17.7% after three injections. These values were statistically significantly higher compared to intact mice (0.6%), the injection of pure plasmid (2.2%), or the intramuscular injection of sucrose (from 0.7 to 1.3%). A relatively high level of transfection (about 5%) was observed after an intracardiac injection of a large dose of the pHSADy (70 micrograms DNA). The perspectives of the targeted delivery of the dystrophin gene into muscles under conditions of parenteral administration are discussed.
authors.affiliation: Ott Institute of Obstetrics and Gynecology, Russian Academy of Medical Sciences, St. Petersburg, Russia.
authors.forename: V S
authors.initials: VS
authors.lastname: Baranov
authors.forename: O V
authors.initials: OV
authors.lastname: Tarasenko
authors.forename: V S
authors.initials: VS
authors.lastname: Baranov
authors.forename: O V
authors.initials: OV
authors.lastname: Tarasenko
authors.forename: A N
authors.initials: AN
authors.lastname: Baranov
authors.forename: A V
authors.initials: AV
authors.lastname: Kiselev
authors.forename: T E
authors.initials: TE
authors.lastname: Ivashchenko
authors.forename: O V
authors.initials: OV
authors.lastname: Evgrafov
authors.forename: V m
authors.initials: Vm
authors.lastname: Mikhailov
authors.forename: G
authors.initials: G
authors.lastname: Dickson
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D002411:Cation Exchange Resins / Q000008:administration & dosage; D004337:Drug Carriers; D016189:Dystrophin / Q000235:genetics*; D005786:Gene Expression Regulation / Q000502:physiology*; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D008055:Lipids / Q000008:administration & dosage; D008081:Liposomes; D008297:Male; D051379:Mice; D018101:Mice, Inbred mdx; D008969:Molecular Sequence Data; D018485:Muscle Fibers, Skeletal / Q000378:metabolism*; D009137:Muscular Dystrophy, Animal / Q000628:therapy; D009842:Oligopeptides / Q000008:administration & dosage; D014162:Transfection
chemical_list: D002411:Cation Exchange Resins; D004337:Drug Carriers; D016189:Dystrophin; D008055:Lipids; C086724:Lipofectamine; D008081:Liposomes; D009842:Oligopeptides